Condition: Lung Cancer · Sponsor: The Institute of Molecular and Translational Medicine, Czech Republic
The trial will evaluate if the newly identified biomarkers of lung cancer in exhaled breath condensate are as a diagnostic tool comparable to the low-dose computer tomography (LDCT) implemented in lung cancer screening recently. Due to the possibility to collect breath condensate at any medical workplace and due to the relatively low financial cost of examination of the collected breath condensate could improve early diagnosis of lung cancer, differential diagnostics of lung nodules and thereby reduce both the unnecessary interventions and deaths from this type of cancer.
This description comes directly from the study's public registry record.
Marian Hajduch, MD, PhD. · +420 585632083 · marian.hajduch@upol.cz
Michaela Bendova, MSc. · +420585632050 · michaela.bendova@upol.cz
Always discuss trial participation with your own doctor first.
| Masaryk Memorial Cancer Institute | Brno, Czechia | Recruiting |
| University Hospital | Olomouc, Czechia | Not Yet Recruiting |
| General University Hospital in Prague | Prague, Czechia | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06016569